Printer Friendly

VESTAR'S DAUNOXOME DESIGNATED ORPHAN DRUG FOR KAPOSI'S SARCOMA

 SAN DIMAS, Calif., May 20 /PRNewswire/ -- Vestar, Inc. (NASDAQ: VSTR) announced today that the Food and Drug Administration has granted Orphan Drug designation to DaunoXome(R), Vestar's proprietary liposomal formulation of the anticancer agent daunorubicin, for the treatment of advanced HIV-associated Kaposi's sarcoma. Vestar submitted a New Drug Application for DaunoXome, the company's second major product, in February.
 The Orphan Drug Act was established in 1983 to provide incentives to pharmaceutical companies to develop products to treat diseases for which the potential patient population is under 200,000 in the United States. Products with Orphan Drug designation are eligible for seven years marketing exclusivity following marketing approval.
 "We're gratified by this recognition for DaunoXome, and view this as an important milestone for the company," said Dr. Roger J. Crossley, Vestar chairman, CEO and president.
 Kaposi's sarcoma is the most common of cancers that afflict AIDS patients, causing a wide spectrum of serious and debilitating symptoms. It is characterized by lesions of the skin, mucous membranes and lymph nodes, and often progresses rapidly to internal organs, including the lungs and gastrointestinal tract. This disease affects an estimated 15 percent or more of AIDS patients.
 Vestar, headquartered in San Dimas, Calif., develops, manufactures and markets pharmaceuticals to treat patients with cancer and serious infections, including AIDS. Since 1989, Vestar has been marketing in Europe AmBisome(R), a liposomal formulation of amphotericin B, to treat systemic fungal infections. DaunoXome, a liposomal formulation of the chemotherapeutic agent daunorubicin, is Vestar's second major product. Among the company's proprietary drug delivery technologies are liposomes to encapsulate pharmaceuticals, and lipid prodrug technology for the development of orally active compounds.
 -0- 5/20/93
 /CONTACT: Michael E. Hart, chief financial officer, Vestar, Inc. 909-394-4119; Marcia A. Kean, executive vice president, Feinstein Partners Inc., 617-577-8110, for Vestar/
 (VSTR)


CO: Vestar, Inc. ST: California IN: MTC SU:

DJ -- NE002 -- 0595 05/20/93 08:32 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 20, 1993
Words:316
Previous Article:INSTANT COUPONS, STADIUM SEATS, LOTTERY TICKETS -- THEY ALL WILL PRINT RIGHT FROM TELEVISION SET VIA NEW INTERACTIVE CABLE CHANNEL
Next Article:FLEET FINANCIAL GROUP FILES TENDER OFFER FOR TWO SERIES OF PREFERRED STOCK
Topics:


Related Articles
VESTAR'S DAUNOXOME (TM) PHASE I/II DATA PRESENTED AT ASH MEETING
VESTAR'S AMBISOME GAINS MARKETING AND REIMBURSEMENT APPROVAL IN SWEDEN
VESTAR, INC. REPORTS DAUNOXOME NOW AVAILABLE ON NAMED-PATIENT BASIS IN EUROPE
VESTAR FILES AMENDED NDA FOR DAUNOXOME
FDA DESIGNATES ANDRULIS PHARMACEUTICALS' THALIDOMIDE AS 'ORPHAN DRUG' FOR AIDS-ASSOCIATED APHTHOUS ULCERS
DAUNOXOME FIRST LINE THERAPY FOR KAPOSI'S SARCOMA NOW AVAILABLE
LIDAK Pharmaceuticals Reports Additional Data From Kaposps Sarcoma Trial At International Conference
IVAX Announces FDA Advisory Panel to Review Paxene(R) for Kaposi's Sarcoma
NeXstar Begins Third Phase II Trial for MiKasome
NeXstar Announces FDA Clearance to Begin Clinical Trials for Anti-Angiogenesis Drug NX 1838

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters